03 jan: FLSmidth/Carnegie: Løfter til "køb"
03 jan: Bavarian får penge i kassen før tid - NY
03-01-2017 11:24:26

Bavarian Nordic Upgrades its Expectations for 2016 Year-end Cash Preparedness

Relateret indhold
17 jan - 
Tirsdagens aktier: Dong og Mærsk positive islæt i eller..
17 jan - 
Aktier/middag: Mærsk og Genmab i top mens markedet vent..
17 jan - 
Aktier/åbning: Goldman giver Genmab gylden håndsrækning
Relateret debat
20 jan - 
ja, ja - det er muligt men nu er jeg langsigtet - følge..
20 jan - 
Så længe shorterne med så få midler kan få den til at f..
20 jan - 
Meget enig!

COPENHAGEN, Denmark, January 3, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that the Company upgrades its expectations for the 2016 year-end cash preparedness from approximately DKK 1,900 million to approximately DKK 2,300 million. The upgrade is primarily a result of payments for IMVAMUNE deliveries, which have been received earlier than expected and to a minor extent the increased USD exchange rate as well as deferred investments. For 2016, the Company maintains its expectations for revenues of approximately DKK 1,000 million and a break-even result before interest and tax.

The full financial statements for 2016 will be published in the annual report on March 15, 2017.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its partner Janssen are developing an Ebola vaccine regimen, which has been fast-tracked, with the backing of worldwide health authorities, and a vaccine for the prevention and treatment of HPV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

Company Announcement no. 01 / 2017

2017-01-en


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Vedhæftet fil: 2017-01-en.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
17 jan
BAVA
Jeg er kongen af zealand pharma og bavarian Nordic!!!!
5
18 jan
BAVA
@Mucho .. man siger en aktie har støtte i et givent området, hvis den før har været handlet en del d..
4
17 jan
BAVA
Er det virkelig rigtige voksene der skriver alt det ? eller er det bare børn der har adgan til EI ?
3
17 jan
BAVA
Du er primitiv i din tankegang - når Bavarian kører op kommentere du aldrig, når den kører ned glæde..
3
20 jan
BAVA
Jeg har samme tanker, at den er for høj lige nu og overvejer også at komme ind i den ved denne kurs...
2
17 jan
BAVA
BAVA er rent TA mæssigt i klemme. Vi har gang i en MACD nedkrydsning, er lige færdig med en lav-volu..
2
17 jan
BAVA
Jeg har solgt på toppen for første gang i mit liv, hurraaaaaaa
2
20 jan
BAVA
Så længe shorterne med så få midler kan få den til at falde, ændrer ingen gamle nyheder på bunden. D..
1
18 jan
BAVA
Jeg har prøvet at finde svar på, om short skal meddeles, når aktien lånes eller når den sælges. Jeg ..
1
18 jan
BAVA
Jeg giver bare udtryk for nogle tanker. Folk har deres egne idéer med deres positioner og vil derfor..
1

Nordea/Sparebank: Hæver kursmål og sænker anbefaling

20-01-2017 16:36:07
Analytikerne hos Sparebank har sænket anbefalingen af Nordea-aktien til "neutral" fra "køb" og hævet kursmålet for aktien. Det viser data fra Bloomberg News.Men..

Mærsk: Kinesisk rival afviser at have budt på Hongkong-rederi

20-01-2017 12:10:51
Kinesiske China Cosco afviser forlydender i kinesisk presse, der går på, at rederiet har lagt et bud på 4 mia. dollar for Hongkong-rederiet Orient Overseas Cont..

Aktier/middag: TDC topper indeks i både Danmark og Europa

20-01-2017 11:44:02
Salgsrygter om teleselskabet TDC får investorerne til at flokkes om aktien, der stiger med 4,2 pct. til 38,52 kr.Og det plus får selskabet til at toppe C20 Cap-..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Bavarian Nordic A/S 272,00 -1,3% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. januar 2017 23:24:09
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170120.2 - EUROWEB2 - 2017-01-22 23:24:09 - 2017-01-22 23:24:09 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x